BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18494271)

  • 1. [Application of monoclonal anti-CD20 antibody rituximab in the treatment of non-Hodgkin's lymphoma].
    Mihaljević B; Janković S; Jaković L; Jovanović MP; Andelić B; Milosević V; Sretenović A; Virijević M; Petrovic M
    Vojnosanit Pregl; 2008 Mar; 65(3):229-33. PubMed ID: 18494271
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
    Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
    Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monoclonal antibody therapy for non-Hodgkin's lymphoma].
    Paul F; Rossi JF; Cartron G
    Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ["Magic bullets"--monoclonal antibodies in acute leukemia and non-Hodgkin's lymphoma treatment].
    Łuczyński W; Krawczuk-Rybak M
    Postepy Hig Med Dosw; 2002; 56(6):789-801. PubMed ID: 12669700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
    Bhat SA; Czuczman MS
    Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody therapy for non-Hodgkin's lymphoma.
    Ansell SM
    Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4. Antibody therapy for malignant lymphoma.
    Tobinai K
    Intern Med; 2007; 46(2):99-100. PubMed ID: 17220608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma.
    Bauduer F
    Br J Haematol; 2001 Mar; 112(4):1085-6. PubMed ID: 11324638
    [No Abstract]   [Full Text] [Related]  

  • 11. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab.
    Schmitz K; Brugger W; Weiss B; Kaiserling E; Kanz L
    Br J Haematol; 1999 Aug; 106(2):571-2. PubMed ID: 10460626
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.
    Hosing C; Saliba RM; Körbling M; Acholonu S; McMannis J; Anderlini P; Giralt S; De Lima M; Okoroji GJ; Couriel DR; Champlin R; Khouri IF; Donato ML
    Leuk Lymphoma; 2006 Jul; 47(7):1290-4. PubMed ID: 16923559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
    Shaw T; Quan J; Totoritis MC
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
    [No Abstract]   [Full Text] [Related]  

  • 15. Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy.
    De Paoli P; Vaccher E; Tedeschi R; Caffau C; Zanussi S; Bortolin MT; Crepaldi C; Spina M; Tirelli U
    Cancer Immunol Immunother; 2001 May; 50(3):157-62. PubMed ID: 11419183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoclonal antibody immunotherapy for malignant non-Hodgkin's lymphoma].
    Jourdan E; Richard B
    Presse Med; 2000 Apr; 29(13):717-21. PubMed ID: 10797826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM; Younes A
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of CD20 expression in relapsed lymphomas after rituximab therapy.
    Haidar JH; Shamseddine A; Salem Z; Mrad YA; Nasr MR; Zaatari G; Bazarbachi A
    Eur J Haematol; 2003 May; 70(5):330-2. PubMed ID: 12694172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New treatment for orbital non-Hodgkin's lymphoma: 2 cases treated with rituximab].
    Benabid L; Desablens B; Defossez T; Malthieu D; Milazzo S; Turut P
    J Fr Ophtalmol; 2005 Sep; 28(7):769-71. PubMed ID: 16208229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.
    Motta G; Cea M; Moran E; Carbone F; Augusti V; Patrone F; Nencioni A
    Clin Dev Immunol; 2010; 2010():428253. PubMed ID: 21437222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.